创始人介绍

Club member

胡朝红,上海美雅珂生物技术有限责任公司,CEO


胡朝红,上海美雅珂生物技术有限责任公司,CEO

个人简介:


Mary Chaohong Hu Biography:


Dr. Mary Chaohong Hu is founder and CEO of Shanghai Miracogen Inc. developing monoclonal antibodies and antibody drug conjugates for cancer therapeutics. She received her BS in Biochemistry from Wuhan University and Ph.D. in Molecular Biology from the Institute of Biophysics, Chinese Academy of Sciences in Beijing, China. She completed her postdoctoral training at the University of Washington, Seattle, Washington. 


She has over 17 years of experience working in the biopharmaceutical/ biotech industry in the US. Before moving back to China, she was Director of Bioassay Development and Process Analytics at Seattle Genetics for development of monoclonal antibodies and antibody-drug conjugates. Prior to joining Seattle Genetics, she was Director of Molecular Biology and Clinical Immunology at GSK /ID Biomedical Corporation and was responsible for preclinical and clinical development of infectious disease vaccines.


公司简介:


上海美雅珂生物技术有限责任公司为中外合资创办,成立于2014年初,选址在人才济济的上海浦东张江高科技园区,目前建有一千五百平米的办公区和洁净实验区,配备高端生物医药人才和世界一流的生物制药仪器设备。


公司致力于癌症靶向治疗新药 – 世界前沿技术抗体偶联药物(Antibody Drug Conjugate,ADC)的研发、临床研究及产业化。公司分别在2017年8月和2018年5月获得两个自主研发的创新ADC药物的CFDA临床批件,并已开展或启动I期临床研究;公司在2018年7月申报了第三个创新ADC药物的IND临床申请;后续多个靶向新药也将以每年一个IND申报的进展速度推进。目前开发的多个靶向治疗ADC新药主要涵盖结直肠癌、食管癌、肺癌、乳腺癌、胃癌和淋巴癌等治疗领域。


公司核心管理团队成员来自于美国GSK, Seattle Genetics等著名跨国生物制药企业,具有数十年丰富的生物制药研发、临床研究、全球法规注册和GMP生产的经验。


公司官网:www.miracogen.com.cn